Suppliers / Maruishi Pharmaceutical

Maruishi Pharmaceutical

Japan Updated 9 July 2026

Maruishi Pharmaceutical is an API manufacturer based in Japan. It holds one active US drug master file.

1
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Alprostadil US FDA 1

Also appears on these molecule pages

Alprostadil API

Questions about Maruishi Pharmaceutical

Does Maruishi Pharmaceutical hold a US DMF or a CEP?
Maruishi Pharmaceutical holds 1 active US drug master file. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Maruishi Pharmaceutical make?
1 molecule is on record against Maruishi Pharmaceutical, including Alprostadil. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Maruishi Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Comparable suppliers

Everlight Chemical Industrial shares 1 molecule Cayman Pharma Sro shares 1 molecule TIEN (Tianjin) Pharmaceutical shares 1 molecule Chinoin Pharmaceutical And Chemical Works shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability